Cosentyx® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adults (alone or in combination with methotrexate) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related arthritis and juvenile psoriatic arthritis in patients 6 years and older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active moderate to severe HS (hidradenitis suppurativa [acne inversa]) in adults with an inadequate response to conventional systemic HS therapy.1,2
For full Cosentyx prescribing information please click here
Cosentyx summary document
This downloadable resource is designed to support you with your local formulary submission or development of treatment guidelines for the use of Cosentyx in adults with hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis or non-radiographic axial spondyloarthritis.
Registration is required to access this resource.
Cosentyx is licensed for the treatment of adults with active moderate to severe HS with an inadequate response to conventional systemic HS therapy1,2
An introduction to hidradenitis suppurativa
Watch this short video for an introduction to HS and the impact it has on patients.
Registration is required to access this resource.
HS formulary application support pack
This resource contains information to support you with your formulary submission and reviewing applications for the use of Cosentyx treatment in HS.
Registration is required to access this resource.
Checklist for the preparation and implementation of Cosentyx for HS in England
This checklist provides you with a list of actions and recommendations you could consider to ensure frictionless local access to reimbursement for Cosentyx in HS.
Registration is required to access this resource.
Cosentyx® formulary application pack for non-radiographic axial spondyloarthritis (nr-axSpA)
This resource is intended to support you with your local formulary submission for the use of Cosentyx in adults with nr-axSpA.
Registration is required to access this resource.
NICE summary card
A summary document from NICE detailing the guidance for the use of Cosentyx in nr-axSpA.
Registration is required to access this resource.
SMC guidance
The SMC guidance for the use of Cosentyx in adults for the treatment of nr-axSpA.
This link will take you to the SMC website, which is a non-Novartis website.
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for full product information before prescribing.1,2
HS, hidradenitis suppurativa; NICE, National Institute for Health and Care Excellence; nr-axSpA, non-radiographic axial spondyloarthritis; SMC, Scottish Medicines Consortium; SmPC, summary of product characteristics.
References:
- Cosentyx® (secukinumab) GB Summary of Product Characteristics.
- Cosentyx® (secukinumab) NI Summary of Product Characteristics.